BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 32600530)

  • 1. Evolving Role of Urologists in the Management of Advanced Renal Cell Carcinoma.
    Kapoor A; Kim J; Goucher G; Hoogenes J
    Urol Clin North Am; 2020 Aug; 47(3):271-280. PubMed ID: 32600530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy.
    Rini BI; Campbell SC
    J Urol; 2007 Jun; 177(6):1978-84. PubMed ID: 17509276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolving role of cytoreductive nephrectomy in metastatic renal cell carcinoma of variant histology.
    Alhalabi O; Karam JA; Tannir NM
    Curr Opin Urol; 2019 Sep; 29(5):521-525. PubMed ID: 31305271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient selection for cytoreductive nephrectomy in combination with targeted therapies or immune checkpoint inhibitors.
    Shapiro DD; Abel EJ
    Curr Opin Urol; 2019 Sep; 29(5):513-520. PubMed ID: 31305274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integration of surgery and systemic therapy for renal cell carcinoma.
    Kenney PA; Wood CG
    Urol Clin North Am; 2012 May; 39(2):211-31, vii. PubMed ID: 22487764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of targeted therapy in combination with surgery in renal cell carcinoma.
    Bex A; Powles T; Karam JA
    Int J Urol; 2016 Jan; 23(1):5-12. PubMed ID: 26238981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted therapy for locally advanced renal cell carcinoma.
    Jonasch E; Tannir NM
    Target Oncol; 2010 Jun; 5(2):113-8. PubMed ID: 20625844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The pathologist's role in the neoadjuvant strategy of renal-cell carcinoma].
    Leroy X; Edeline J; Rioux-Leclercq N
    Ann Pathol; 2011 Dec; 31(6):466-71. PubMed ID: 22172119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant Therapy for Locally Advanced Renal Cell Carcinoma.
    Westerman ME; Shapiro DD; Wood CG; Karam JA
    Urol Clin North Am; 2020 Aug; 47(3):329-343. PubMed ID: 32600535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Survival following Initial Cytoreductive Nephrectomy versus Initial Targeted Therapy for Metastatic Renal Cell Carcinoma.
    Bhindi B; Habermann EB; Mason RJ; Costello BA; Pagliaro LC; Thompson RH; Leibovich BC; Boorjian SA
    J Urol; 2018 Sep; 200(3):528-534. PubMed ID: 29574109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is cytoreductive nephrectomy relevant in the immunotherapy era?
    Singla N; Ghandour RA; Margulis V
    Curr Opin Urol; 2019 Sep; 29(5):526-530. PubMed ID: 31305273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of cytoreductive nephrectomy in patients with renal cell carcinoma.
    Ghandour RA; Singla N; Margulis V
    Expert Rev Anticancer Ther; 2019 May; 19(5):405-411. PubMed ID: 31020871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytoreductive nephrectomy in metastatic renal cell carcinoma: the evolving role of surgery in the era of molecular targeted therapy.
    Kwan KG; Kapoor A
    Curr Opin Support Palliat Care; 2009 Sep; 3(3):157-65. PubMed ID: 19528804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TARIBO trial: targeted therapy with or without nephrectomy in metastatic renal cell carcinoma: liquid biopsy for biomarkers discovery.
    Verzoni E; Ratta R; Grassi P; Salvioni R; Stagni S; Montone R; Fucà G; Cappelletti V; Reduzzi C; De Giorgi U; Procopio G
    Tumori; 2018 Oct; 104(5):401-405. PubMed ID: 29192741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic therapy in the management of localized and locally advanced renal cell carcinoma: Current state and future perspectives.
    Berquist SW; Yim K; Ryan ST; Patel SH; Eldefrawy A; Cotta BH; Bradshaw AW; Meagher MF; Bindayi A; McKay RR; Autorino R; Staehler M; Derweesh IH
    Int J Urol; 2019 May; 26(5):532-542. PubMed ID: 30943578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytoreductive nephrectomy vs medical therapy as initial treatment: a rational approach to the sequence question in metastatic renal cell carcinoma.
    Spiess PE; Fishman MN
    Cancer Control; 2010 Oct; 17(4):269-78. PubMed ID: 20861814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: combining surgery and systemic therapies to improve patient outcome.
    Wood CG
    Clin Cancer Res; 2007 Jan; 13(2 Pt 2):697s-702s. PubMed ID: 17255296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The evolving role of cytoreductive surgery for metastatic renal cell carcinoma.
    Chaudhary UB; Hull GW
    Oncology (Williston Park); 2003 May; 17(5):701-5; discussion 705-6, 711-2. PubMed ID: 12800795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nephrectomy for metastatic renal-cell cancer.
    Copur MS; Ledakis P; Norvell M
    N Engl J Med; 2002 Apr; 346(14):1095-6. PubMed ID: 11936126
    [No Abstract]   [Full Text] [Related]  

  • 20. Multimodal treatment of advanced renal cancer in 2017.
    Mennitto A; Verzoni E; Grassi P; Ratta R; Fucà G; Procopio G
    Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1395-1402. PubMed ID: 28956645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.